Spain · Delayed Price · Currency is EUR Grifols Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 2.6% in H1 2026, led by Biopharma and strong IG demand, with adjusted EBITDA up 2.4% and free cash flow improving by EUR 103 million year-over-year. Albumin in China stabilized, diagnostics advanced with new launches, and the company remains on track for its 2026 guidance.
Fiscal Year 2025
-
Targets €10 billion revenue by 2029 and €14 billion by 2034, with a focus on biopharma-led growth, margin expansion, and innovation. Operational improvements, disciplined capital allocation, and new product launches underpin a 7% revenue CAGR and 10% EBITDA CAGR through 2029.
Fiscal Year 2024
-
Record revenues and EBITDA were achieved in 2024, driven by strong Biopharma growth and operational efficiencies. Free cash flow and deleveraging exceeded expectations, while innovation and sustainability advanced. Guidance for 2025 and further strategic details will be shared at Capital Markets Day.
-
Q3 2024 saw double-digit revenue and EBITDA growth, improved free cash flow, and reduced leverage, with Biopharma and IG franchises leading performance. Management remains confident in meeting full-year guidance and further deleveraging, supported by strong demand and operational improvements.